Talazoparib was taken by patients with advanced BC carrying BRCA1/2 germline mutation in the EMBRACA trial, showing notably longer PFS (8.6 months versus 5.6 months) in the talazoparib arm versus the chemotherapy arm and objective response rate (ORR) was improved (62.6% versus 27.2%) [35]. This evidence concerns the gene BRCA1 and breast cancer.